Sam Altman says curing cancer with AI is not enough, urges the industry to aim higher

Sam Altman is tired of the cancer pitch. Speaking on Bloomberg Television on September 4, 2026, the OpenAI CEO told the industry to stop treating “AI will cure cancer” as the ceiling of ambition and start treating it as the floor. His argument is straightforward: a technology capable of reordering civilization deserves a grander public case than a single, still-unrealized medical milestone. Altman said AI should instead unlock a broad surge in human creativity and entrepreneurship, putting more power in individual hands rather than concentrating it at the top. A narrative problem the industry created for itself Anthropic CEO Dario Amodei made a similar point in August 2026, calling the “AI will cure cancer” messaging closer to cliché than inspiration. Pew Research data shows roughly 40% of Americans now expect AI to have a negative impact on society. No AI-designed drug has successfully cleared clinical trials and received approval for use, despite years of well-funded efforts from dozens of companies. What “aiming higher” actually means Physician-researcher Emilia Javorsky has argued that intelligence itself is not the primary barrier in cancer research. The bottlenecks are biolog...